Breakthrough in 9 months – Primary Progressive Multiple Sclerosis (PPMS)  Congratulations Michael. The case of Michael Witmer, diagnosed with PPMS in April 2025, demonstrating a significant shift in restorative neurology with confirmed NEDA status (No Evidence of Disease Activity) and structural lesion remission. 

Double Objective Evidence of Success:

1. Serological Reversal: At baseline in May 2025, Michael tested ANA positive, confirming active B-lymphocyte-mediated autoimmunity. Following the neurogenesis protocol at Somata Genesis, consecutive follow-up tests in October 2025 and March 2026 returned negative. This confirms a durable halt in detectable autoimmune activity without any exposure to classic immunosuppression or chemotherapy. 
2. Radiological Remission: A comparison between Michael’s baseline MRI (May 2025) and a follow-up scan in February 2026 reveals that his prominent “smouldering” cervical spinal lesion at C2-C3 has transitioned into a non-active state. Furthermore, a pre-existing brain stem lesion was confirmed to have reversed during this 9-month follow-up period. 

Key Highlights:

• Halt in Relapses: No new disease activity recorded post-therapy. 
• Lesion Transition: Active spinal damage successfully stabilized into a state of remission. 
• Restorative Approach: Success was achieved via a non-destructive cellular approach focused on immune re-balancing and neuro-restoration. 

This case challenges the necessity of chronic, life-long immunosuppression for MS and highlights the potential of early intervention with targeted regenerative solutions to “rebuild the structure” rather than just manage the decline.

More details here: 

#MultipleSclerosis #PPMS #Neurogenesis #SomataGenesis #NEDA #MedicalBreakthrough#stemcell #StemCellTherapy